| Date | Title | Description | |
|---|---|---|---|
| 25 Mar 2025 | On business and financial situation | The Company releases the presentation related to its strategy update because of its 2025 Capital Markets Day | Download |
| 25 Feb 2025 | On P&L | The Company releases the press release related to the full year 2024 financial results | Download |
| 25 Feb 2025 | On P&L | The Company releases the full year 2024 financial results presentation | Download |
| 25 Feb 2025 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 07 Feb 2025 | On P&L | The Company informs on some of the results expected by the market consensus | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 19 April and 25 April 2024 | Download |
| 19 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 12 April and 18 April 2024 | Download |
| 12 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 5 April and 11 April 2024 | Download |
| 05 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 28 March and 4 April 2024 | Download |
| 02 Apr 2024 | On business and financial situation | ROVI informs on the FDA’s approval of Risvan® as a treatment for schizophrenia | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 21 Feb 2012 | Información sobre resultados (2) | Download | |
| 21 Feb 2012 | Información sobre resultados | Download | |
| 21 Feb 2012 | Informe Anual de Gobierno Corporativo | Download | |
| 15 Feb 2012 | Cambios en política de inversión, áreas de negocio y líneas de productos | Download | |
| 22 Dec 2011 | Composición del Consejo de Administración | Download |